

Application No.: 10/717,290

**Amendments to the Claims:**


Please amend claims 24 and 41.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing:**

1-23. (Cancelled)

24. (Currently Amended) A compound represented by formula:




and or a pharmaceutically acceptable salts salt, esters ester, ~~prodrugs~~ prodrug, racemic mixtures mixture and or stereoisomers stereoisomer thereof.

25. (Previously Presented) A compound according to claim 24 wherein the compound is a pharmaceutically acceptable salt.
26. (Previously Presented) A compound according to claim 24 wherein the compound is a free base.
27. (Previously Presented) A compound according to claim 24 wherein the compound is an ester or prodrug.
28. (Previously Presented) A compound according to claim 24 wherein the compound is an E oxime isomer.

Application No.: 10/717,290

29. (Previously Presented) A compound according to claim 24 wherein the compound is a *Z* oxime isomer.
30. (Previously Presented) A method for treating an infection or a disorder related to an infection in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a compound according to the formula:



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof.

31. (Previously Presented) A method according to claim 30 wherein the compound is pharmaceutically acceptable salt.
32. (Previously Presented) A method according to claim 30 wherein the compound is a free base.
33. (Previously Presented) A method according to claim 30 wherein the compound is an ester or prodrug.

Application No.: 10/717,290

34. (Previously Presented) A method according to claim 30 wherein the compound is an E oxime isomer.
35. (Previously Presented) A method according to claim 30 wherein the compound is a Z oxime isomer.
36. (Previously Presented) The method according to claim 30 wherein the compound is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
37. (Previously Presented) The method according to claim 30 wherein the compound is administered orally or by injection.
38. (Previously Presented) The method according to claim 30 wherein the subject is a human.
39. (Previously Presented) The method according to claim 30 wherein the compound is administered in combination with one or more antibiotics.
40. (Previously Presented) The method according to claim 39 wherein the antibiotic is selected from the group consisting of penicillin, amoxicillin, azithromycin, erythromycin, ciproflaxin, telithromycin, and cethromycin or a pharmaceutically acceptable salt, ester, or prodrug thereof.
41. (Currently Amended) The method according to Claim 30 wherein the infection is a protozoa infection or bacterial infection ~~and~~ or disorders related to such infections.
42. (Previously Presented) The method according to Claim 41 wherein the infection or disorder is selected from the group consisting of pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by


Application No.: 10/717,290

*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus*, or *Peptostreptococcus* spp. *Pseudomonas* spp.; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by *Streptococcus pyogenes*, Groups C and G streptococci, *Clostridium diphtheriae*, or *Actinobacillus haemolyticum*; respiratory tract infections related to infection by *Mycoplasma pneumoniae*, *Legionella pneumophila*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, or *Chlamydia pneumoniae*; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by *Staphylococcus aureus*, coagulase-positive staphylococci, *S. pyogenes*, *S. agalactiae*, Streptococcal groups C-F, viridans streptococci, *Corynebacterium* spp., *Clostridium* spp., or *Bartonella henselae*; uncomplicated acute urinary tract infections related to infection by *S. saprophyticus* or *Enterococcus* spp.; urethritis and cervicitis; and sexually transmitted diseases related to infection by *Chlamydia trachomatis*, *Haemophilus ducreyi*, *Treponema pallidum*, *Ureaplasma urealyticum*, or *Nisseria gonorrhoeae*; toxin diseases related to infection by *S. aureus*, or Groups A, S, and C streptococci; ulcers related to infection by *Helicobacter pylori*; systemic febrile syndromes related to infection by *Borrelia recurrentis*; Lyme disease related to infection by *Borrelia burgdorferi*; conjunctivitis, keratitis, and dacrocystitis related to infection by *C. trachomatis*, *N. gonorrhoeae*, *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenzae*, or *Listeria* spp.; disseminated *Mycobacterium avium* complex (MAC) disease related to infection by *Mycobacterium avium*, or *Mycobacterium intracellulare*; gastroenteritis related to infection by *Campylobacter jejuni*; intestinal protozoa related to infection by *Cryptosporidium* spp. odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by *Bordetella pertussis*; gas gangrene related to infection by *Clostridium perfringens* or *Bacteroides* spp.; Skin infection by *S. aureus*, *Propionibacterium acne*; atherosclerosis related to infection by *Helicobacter pylori* and *Chlamydia pneumoniae*.

Application No.: 10/717,290

43. (Previously Presented) The method according to Claim 42 wherein the infection is selected from the group consisting of pneumonia, otitis-media, sinusitis, bronchitis, tonsillitis, *Propionibacterium acne* and skin and soft tissue infection.
44. (Previously Presented) The method according to Claim 41 wherein the infection or disorder is selected from the group consisting of bovine respiratory disease related to infection by *P. haemolytica*, *P. multocida*, *Mycoplasma bovis*, or *Bordetella* spp.; cow enteric disease related to infection by *E. coli* or protozoa, dairy cow mastitis related to infection by *S. aureus*, *S. uberis*, *S. agalactiae*, *S. dysgalactiae*, *Klebsiella* spp., *Corynebacterium*, or *Enterococcus* spp.; swine respiratory disease related to infection by *A. pleuropneumoniae*, *P. multocida*, or *Mycoplasma* spp.; swine enteric disease related to infection by *E. coli*, *Lawsonia intracellularis*, *Salmonella* spp., or *Serpulina hyodysenteriae*; cow footrot related to infection by *Fusobacterium* spp.; cow metritis related to infection by *E. coli*; cow hairy warts related to Infection by *Fusobacterium necrophorum* or *Bacteroides nodosus*; cow pink-eye related to infection by *Moraxella bovis*, cow premature abortion related to infection by protozoa; urinary tract infection in dogs and cats related to infection by *E. coli*; skin and soft tissue infections in dogs and cats related to infection by *S. epidermidis*, *S. intermedius*, coagulase neg. *Staphylococcus* or *P. multocida*; and dental or mouth infections in dogs and cats related to infection by *Alcaligenes* spp., *Bacteroides* spp., *Clostridium* spp., *Enterobacter* spp., *Eubacterium* spp., *Peptostreptococcus* spp., *Porphyromonas* spp., *Campylobacter* spp., *Actinomyces* spp., *Erysipelothrix* spp., *Rhodococcus* spp., *Trypanosoma* spp., *Plasmodium* spp., *Babesia* spp., *Toxoplasma* spp., *Pneumocystis* spp., *Leishmania* spp., and *Trichomonas* spp. and *Prevotella* spp.
45. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

Application No.: 10/717,290



and pharmaceutically acceptable salts, esters, prodrugs, racemic mixtures and stereoisomers thereof, in combination with a pharmaceutically acceptable carrier.

46. (Previously Presented) A method for controlling a bacterial infection in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 45.